Sy Mukherjee, Fortune

Sy Mukherjee


New York, NY, United States

Contact Sy

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Fortune

Recent articles by Sy:

Why This Kids' Epilepsy Drug Is Almost Certainly About to Become the 1st FDA Approved Marijuana Treatment

With unanimous FDA panel backing, it'd shocking if GW Pharma's "breakthrough" cannabis drug gets rejected. → Read More

UPDATED: Rare Disease Drug Maker Shire's Stock Spikes Amid Possible Bidding War Between Allergan and Takeda

Shire has already rebuffed a $62.5 billion offer from Japan's Takeda. → Read More

What We Know About the Mysterious Flesh-Eating Bacteria Spreading in Australia

The nasty pathogen causes a condition called a Buruli ulcer. → Read More

How Big Data Is Fueling This Company's Digital War on Diabetes

Data is at the heart of Omada's diabetes- and obesity-fighting strategy. → Read More

Brainstorm Health: Digital Diabetes Prevention, Cannabis-Based Drug, UnitedHealth Earnings

Hello there, readers! This is Sy. Omada Health pulled of something that was, especially at the time, highly unusual in the ever-burgeoning yet still-fledgling digital health space: In 2016, the company scored federal government reimbursements for its diabetes prevention program. It’s continued to grow since then and shared results from nine different peer-reviewed studies noting significant… → Read More

UnitedHealth Weathers a Tough Flu Season to Smash Wall Street Earnings Expectations

The health insurance giant's Optum unit is on a serious roll. → Read More

Brainstorm Health: Merck's Lung Cancer Triumph, COPD and Women, Trump on Drug Prices

Hello and happy Monday, readers! This is Sy. New study results released Monday continue to cement drug giant Merck’s status as the force to be reckoned with in the lung cancer treatment space. Merck’s flagship cancer immunotherapy Keytruda (or pembrolizumab), combined with chemotherapy, helped lung cancer patients live significantly longer lives than those treated with chemotherapy alone. It’s… → Read More

Merck's Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. → Read More

Goldman Sachs: China Is Beating the U.S. in the Gene Editing Arms Race

On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says. → Read More

Tesla Stock Spikes After Elon Musk Predicts 2018 Profits In Snarky Tweet at 'The Economist'

Musk said Tesla will be cash flow positive in the second half of the year. → Read More

Brainstorm Health: Gene Editing Arms Race, Pfizer Duchenne Drug, Concentrated Caffeine

Happy Friday, readers! This is Sy. In recent years, the advent of gene editing and cell-engineering technologies to fight rare diseases, cancer, and a number other serious conditions has taken the biopharma world by storm across the globe. The Food and Drug Administration (FDA) approved therapies known as “CAR-T”, from Novartis and Gilead/Kite Pharma, that re-engineer patients’ own immune cells… → Read More

This Tech Gave the ALS Ice Bucket Challenge's Co-Founder His Own Voice Back After He'd Lost It

"Project Revoice" aims to help patients with ALS, the condition Stephen Hawking struggled with. → Read More

Hepatitis C Drugs Can Cost $84,000. This New One May Be Just As Good—But Cost $300

A $300 hepatitis C drug being developed by a nonprofit may prove just as effective as $84,000 hep C cures from companies like Gilead. → Read More

Brainstorm Health: ALS Voice Recreation, $300 Hep C Drug, Opioid Lawsuits

Hello, readers! Sy at your service. Amyotrophic lateral sclerosis, commonly called ALS or Lou Gehrig’s disease, is a devastating, degenerative neurological disorder. Its cruelties include robbing patients of activities we often take for granted, like walking, eating, talking, and even breathing. But a new tech initiative could help restore ALS patients’ most personal attributes: Their very… → Read More

Marijuana Stocks Spike After Ex-House Speaker John Boehner Joins Cannabis Company Board

Boehner cited an evolution in his thinking and the opioid crisis as motivations for his move. → Read More

Here's How Much Less Women and Black Doctors Make Than Their White Male Colleagues

Doctors' salaries are rising, but so is pay inequality. → Read More

Brainstorm Health: Boehner Joins Marijuana Company, Alzheimer's Gene Deletion, Doctor Pay Gap

Hello and happy hump day, readers! This is Sy. The gender and racial pay gap extends into pretty much every industry, including high-skill, high-stress fields like medicine. In fact, white or male doctors make tens of thousands of dollars—and even up to $100,000—more, on, average than women or minority physicians, according to a new survey. Medscape’s 8th annual Physician Compensation Report… → Read More

Report: Theranos Just Laid Off the Vast Majority of Its Employees

Elizabeth Holmes' firm may now have fewer than two dozen employees remaining. → Read More

Researchers Just Proposed a Radical New Way of Defining Alzheimer's. Could It Lead to Better Drugs?

Alzheimer's drug development has been a tale of heartbreaks and setbacks. → Read More

Brainstorm Health: Alzheimer's Definition, At-Home DNA Tests, UnitedHealth's Reach

Hello there, readers! This is Sy. Alzheimer’s has long been one of the heaviest therapeutic albatrosses slung round drug developers’ necks. The memory-eating disease, expected to afflict 15 million Americans by 2060 (and tens of millions more around the world as life expectancy increases), has no cure; a new drug for the condition hasn’t been approved in well over a decade; initially promising… → Read More